﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 10:16:49 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>Myriad Genetics, Inc., Selects Topin &amp; Associates to Market OnDose® Dose Optimization Technology</title><link>http://news.cision.com/myriad-genetics/r/myriad-genetics--inc--selects-topin---associates-to-market-ondose--dose-optimization-technology,g9126979</link><guid isPermaLink="false">cision351160</guid><description><![CDATA[CHICAGO – May 24, 2011 – Myriad Genetics, Inc., has selected Topin & Associates (topin.com) to support the ongoing marketing of OnDose Dose Optimization Technology to the oncology marketplace. OnDose is Myriad Genetics’ seventh molecular diagnostic product and an important entry in its personalized medicine product line. It utilizes proprietary technology to measure a patient’s exposure to the chemotherapy drug 5-Fluorouracil (5-FU), providing information with which a physician can optimize the dose of 5-FU to help maximize efficacy and reduce toxicity. Topin & Associates, along with its]]></description><pubDate>Wed, 25 May 2011 13:30:00 GMT</pubDate></item></channel></rss>